Expansion of the Territory Sample Clauses

Expansion of the Territory. The parties hereby acknowledge and agree -------------------------- that, as of the Effective Date, the Territory shall be limited to the U.S. Cytogen hereby grants to Bard a right of first offer to expand the Territory to include one (1) or more of the Selected Countries, subject to relinquishment by CIS and Faulding of their respective rights of first negotiation to market and promote Product to Urologists in the Selected Countries. In the event CIS notifies Cytogen that it relinquishes its said right of first negotiation with respect to one or more of the Selected Countries (other than Canada) or in the event Faulding notifies Cytogen that it relinquishes its said right of first negotiation with respect to Canada (a "Waiver Notice"), Cytogen, within thirty (30) business days of its
Sample 1Sample 2
AutoNDA by SimpleDocs
Expansion of the Territory. Sankyo is hereby granted options to add Japan and the European Union (which shall mean those countries which make up the European Union as of the Effective Date and the additional countries of Norway and Switzerland) to the Territory. The options for Japan and the European Union shall individually expire on [ * ]. Should Sankyo decide to so expand the Territory, it shall provide GelTex with written notice of such decision prior to the expiration of the option, and following GelTex's receipt of such written notice, the definition of the Territory shall be revised to include the additional countries and/or territories specified in such notice. As part of its due diligence obligations Sankyo shall be required to: (i) commence Phase I clinical trials of Compound in Japan within [ * ] of adding Japan to the Territory; and (ii) file a Marketing Authorization Application in the European Union (or equivalent regulatory submissions in at least two countries of the European Union designated by the mutual agreement of the Parties) within [ * ] after the NDA for Compound is filed in the United States. If Sankyo fails to meet either of the due diligence [ * ] Confidential information omitted and filed separately with the Commission.
Sample 1Sample 2
Expansion of the Territory. 5.1 PharmaPrint hereby grants AHP, and AHP accepts, an option to expand the Territory to further include any countries other than the United States of America.
Sample 1
Expansion of the Territory. At any time during the initial twelve (12) months of the Term of this Agreement, WYETH shall have the right and option to negotiate for the addition of countries or geographic areas to the Territory. Such right is exercisable by delivery of written notice to ACCESS, specifying the countries or geographic areas with respect to which WYETH would like to add to the Territory, and is subject to mutual agreement of the Parties. Upon receipt of such notice, the Parties shall negotiate in good faith the terms of the exclusive or non- exclusive (as the parties may mutually agree) arrangement with respect to the additional countries or geographic areas. In the event that the Parties are unable to reach agreement on such terms on or prior to the 60th day following commencement of such negotiations, ACCESS shall bear no further obligation to WYETH under this Section 2.7 with respect to the applicable countries or geographic area; provided that ACCESS shall not thereafter enter into or be a party to any arrangement, agreement, license or distribution relationship with a Third Party with respect to the Product in all or any portion of the applicable countries or geographic areas on terms and conditions in the aggregate more favorable to such Third Party than the aggregate terms and conditions offered to WYETH without first offering such aggregate terms and conditions to WYETH.
Sample 1
Expansion of the Territory. (a) During the Term, [***] shall have [***] to obtain [***] in the [***]. Epirus shall [***] with any [***] to obtain [***] in the [***]. In the event that Epirus and Ranbaxy have [***] pursuant to which [***] such a [***] in the [***], Epirus shall [***] for the [***] in the [***].
Sample 1
Expansion of the Territory. Nextel shall have the option, at anytime during the term of this Agreement, to expand the Territory subject to the terms of this Section 2.10. In the event Nextel desires to expand the Territory, then: (i) Nextel shall provide LCC with thirty (30) days prior written notice setting forth the name(s) of any additional nations to be added to the Territory and the date that Nextel first expects to use the Software in or for that nation, (ii) the monthly software license fee set forth in Exhibit B, Section 1 hereto shall be increased, effective on the first day of the month in which the expansion becomes effective, by an amount equal to [___________] times the number of computer video display terminals ("Workstations") used by Nextel in such additional nation(s) during the month prior to each monthly payment, and (iii) the monthly Support and Maintenance Fees set forth in Exhibit B, Section 2 shall be increased, effective as set forth above, by an amount equal to [______] times the number of Workstations over which either the CellCAD Software or the ANET Software is used by Nextel in such additional nation(s) during the month prior to said monthly payment.
Sample 1
Expansion of the Territory. Should the Company wish to expand the Territory to include lsrael, Cyprus and/or any other country in the Middle East, the Licensors shall favorably consider such request, provided that the Company shall grant Hadasit a right of first refusal to set up treatment centers, with the use of the Products, in any such countries.
Sample 1
AutoNDA by SimpleDocs
Expansion of the Territory. Under Section 1.60 of the Current Agreement, the Territory is defined as “the U.S., Canada, and Mexico and their respective territories, protectorates and possessions.” On the Amendment Effective Date, the Territory as defined in the Current Agreement (the “Original Territory”), and the license granted to Catalyst under Section 2.1 of the Current Agreement, shall be expanded to include, Japan and its territories, protectorates and possessions. Further, upon acceptance by the MHLW of a Japan MAA for a Licensed Product for LEMS, the Territory, and the license granted to Catalyst under Section 2.1 of the Agreement, shall be further expanded to also include all the countries in
Sample 1
Expansion of the Territory. Licensor shall provide to Licensee a right of first refusal on any license proposed to be granted by Licensor to any third party for use of the Technology outside the Territory but in the Industry, affording Licensee the opportunity to extend the Territory on terms and conditions at least as favorable as those proposed to be granted under the proposed transaction. In addition, Licensor shall expand the Territory upon written request of Licensee, provided (a) Licensor has not granted rights to any third party in the geographic area requested, and (b) Licensee can make a commercially reasonable showing that that Licensee has a bona fide business opportunity in such region. In the event Licensee is not successful in consummating a sublicense of the Technology hereunder in such expanded Territory, such region shall revert to Licensor in a reasonable time.
Sample 1

Related to Expansion of the Territory

  • Commercialization Activities Within North America, the Parties will use Commercially Reasonable Efforts to Commercialize Licensed Products in the Field. In addition, within North America and subject to Section 2.7.6, the Parties will use Commercially Reasonable Efforts to conduct the Commercialization activities assigned to them pursuant to the Commercialization Plan/Budget, including the performance of detailing in accordance therewith. In conducting the Commercialization activities, the Parties will comply with all Applicable Laws, applicable industry professional standards and compliance policies of Celgene which have been previously furnished to Acceleron, as the same may be updated from time to time and provided to Acceleron. Neither Party shall make any claims or statements with respect to the Licensed Products that are not strictly consistent with the product labeling and the sales and marketing materials approved for use pursuant to the Commercialization Plan/Budget.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Commercialization License Subject to the terms of this Agreement, including without limitation Section 2.2 and Theravance's Co-Promotion rights in Section 5.3.2, Theravance hereby grants to GSK, and GSK accepts, an exclusive license under the Theravance Patents and Theravance Know-How to make, have made, use, sell, offer for sale and import Alliance Products in the Territory.

  • Development of the Project The Board of Managers shall take such actions as shall be required to cause either the Company or the Management Company (as defined in Section 9(b) below) to perform and complete the construction and other development work as contemplated and/or required under the NVR Purchase and Sale Agreements, or any other construction company selected by the Board of Managers (the “Development Work”), substantially in accordance with the Project Plan, at a cost to the Company not exceeding the total cost set forth in the Budget, in a manner consistent with this Agreement and all applicable laws, ordinances, rules, regulations or requirements (including, without limitation, those with respect to discrimination) of governmental authorities, and in compliance with any covenants, conditions or restrictions affecting all or any portion of the Property.

  • Development Activities NovaDel shall not be required to commence any Development Activities until Licensee has paid at least twenty-five percent (25%) of the non-refundable License Fee described in Section 4.4.

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

  • Licensed Territory Worldwide NIH Patent License Agreement—Exclusive APPENDIX C – ROYALTIES Royalties:

  • Development Work Do, or cause to be done, such development and other work as may be reasonably necessary to protect from diminution and production capacity of the Mortgaged Property and each producing well thereon.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Territory The territorial limits of this Agreement shall be identical with those of the Reinsured Contracts.

Time is Money Join Law Insider Premium to draft better contracts faster.